Direct Flow Medical Launches Next Generation TAVI Delivery System

 

Direct Flow Medical Launches Next Generation TAVI Delivery System

SANTA ROSA, Calif.– March 28, 2016 – Direct Flow Medical, Inc., a medical device company developing and commercializing transcatheter heart valve therapy products to treat structural heart disease, today announced European commercial market launch of the DirecTrack™ Delivery System, a next generation delivery system for the Direct Flow Medical Transcatheter Aortic Valve System.

The Direct Flow Medical transcatheter aortic valve system, with more than 2,500 implants and excellent published clinical results including low rates of paravalvular leak, pacemaker implant, and mortality, is the only non-metallic, conformable transcatheter aortic valve that can be functionally assessed, repositioned, and retrieved prior to final implant.

The next generation DirecTrack Delivery System features advanced ergonomic design and functionality to provide physicians with greater procedural control during valve implantation.  “I have had the opportunity to use every generation of the Direct Flow Medical delivery system since its inception. The new DirecTrack system is a major step forward in positioning control and smooth valve delivery” stated Joachim Schofer, M.D., Professor of Cardiology, Hamburg University Cardiovascular Center, Hamburg.  He continued, “I’m impressed with the additional procedural efficiency gained, making it faster and easier to achieve an optimal outcome.”

“We’re pleased to provide physicians with this latest advance in TAVI procedural control” stated Dan Lemaitre, President and CEO, Direct Flow Medical.  He said, “The DirecTrack Delivery System provides all the features of our prior delivery system but with significantly enhanced ergonomics and precision to assure the best possible clinical outcome.”

About Direct Flow Medical, Inc.

Direct Flow Medical, Inc. is a privately-held medical device company developing and commercializing novel transcatheter heart valve therapy products to treat structural heart disease.

The company is sponsoring the SALUS Pivotal Trial in the U.S. to investigate the Direct Flow Medical Transcatheter Aortic Valve System for treatment of high and extreme risk severe symptomatic aortic stenosis.  The system is commercially available in Europe for treatment of patients with aortic stenosis who are at extreme surgical risk.

Company website:  directflowmedical.com

Media contact:

Brian McIntee
Direct Flow Medical, Inc.
bmcintee@directflowmedical.com
+1 (707) 576-0420

The Direct Flow Medical Transcatheter Aortic Valve System is commercially available in Europe and an investigational device in the U.S.  Direct Flow Medical, DirecTrack, and the Direct Flow logo are trademarks of Direct Flow Medical, Inc.

 

 

The information on this site is only intended for health care providers in certain markets outside the United States (US) where the Direct Flow Medical Trancatheter Aortic Valve Replacement System is approved for use as indicated by the instructions for use. The information on this page is not intended for health care providers in the US or US health care institutions as this site contains information about a product that is limited by US law to investigational use.

I am a health care
provider in the
United States
I am a health care
provider outside
the United States